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Abstract 
 
Lassa fever virus (LASV) infects thousands of people and produces more than 5,000 deaths each year in 
West Africa. This severe virus is a huge threat, as it transmits between human and rodents, and no effective 
vaccine or drug is available currently. One key of getting control of this disease lies in the nucleoprotein 
(NP) of LASV, which plays an essential role in viral replication, transcription and immune suppression. 
The full length NP crystal structure has been solved, showing a novel structural fold and multi-functions 
with unusual mechanisms in immune suppression and viral RNA transcription.  
The C-terminal domain of LAVS NP is a 3’-5’ exonuclease, whose activity is essential for viral immune 
suppression. This domain alone can suppress an immune response and can degrade dsRNAs with specific 
preference higher than for ssRNAs. However, the detail of the mechanism is unclear. To understand the 
mechanism while avoiding another domain’s effect (the N-terminal domain), the C-terminal domain of 
LASV NP was expressed and purified, and pathogen-associated pattern molecular RNAs were synthesized 
chemically and biologically to carry on crystallization and functional testing. The C-domain crystals in 
complex with a pathogen-associated pattern molecule, triphosphate 8 nucleotide dsRNA were obtained. 
The crystal belongs to the space group P3 with unit cell dimension a=b=177.6 Å, c=56.49Å, α =β=90°, 
γ=120°. This crystal structure showed that the dsRNA binds in the 3’-5’ exonuclease active site with one 3’ 
end of the dsRNA perfectly sitting for cleavage. We are trying to figure out the detailed mechanism by 
mutagenesis, fluorescence-labeled RNA gel scan and band shift assays. 
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1 INTRODUCTION 
1.1 LASSA FEVER 
1.1.1 BACKGROUND 
Lassa fever is a hemorrhagic illness caused by Lassa virus. It is first described in the town of Lassa, Nigeria in 
1969, when two missionary nurses died there. It spread endemically across West Africa, mainly in Nigeria, 
Guinea, Liberia and Sierra Leone. Lassa fever cases are also been reported in Europe, America and Asia, due to 
people travelling to epidemic areas. (Ogbu O, et al., 2007) 
 
Lassa virus (LAV) has high mortality and no effective vaccine. It causes 300,000 to 500,000 infections and 
5000 deaths yearly, (Walter HH, et al., 2003) with 15% to 20% hospitalized patients’ death and 50% fatality 
during epidemics. The Center of Disease Control and Prevention of USA classified Lassa fever virus as a 
biosafety level 4 agent, for it is airborne transmission. (Illick MM, et al., 2003)  
1.1.2 TRANSMISSION  
The wide distribution of Lassa fever is mainly caused by infected Mastomys rodents. They can instigate the 
virus' spreading by direct contacting human, contaminating foods with their secretions, or spreading tiny virus 
particles from excretions in the air which might inhaled by people. Since rodent distributes very close to human 
living range and lives undetectably, Lassa fever transmission becomes hard to control. 
 
 
Fig 1: The Lassa fever virus host, Mastomys rodent. 
(Picture from: viral hemorrhagic fever consortium website) 
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Lassa fever can also transmit from person to person, via blood, tissue, secretions, or excretions of an individual 
infected with the Lassa virus. However, casual contact, such as skin to skin without exchange of body fluids 
might not spread the disease. On the other hand, both men and women, young and old can be infected. And the 
pregnant women and infants are among the most risky group. (The center of Disease Control and Prevention, 
December 3, 2004) 
 
 
Fig 2: Risk Map of Lassa fever in West Africa (Picture from Fichet E, Rogers DJ. 2009) 
1.1.3 PATHOGENESIS 
The incubation period of Lassa fever ranges from 6 to 21 days, and the onset duration is 1to 4 weeks. This acute 
illness will harm several organs in the body, such as the liver, spleen and kidneys. The disease usually begins 
with fever, general weakness, and malaise, following by headache, sore throat, muscle pain, chest pain, nausea, 
vomiting, diarrhea, cough, and abdominal pain in a few days later. In extreme situations, patients may suffer 
facial swelling, fluid in the lung cavity, bleeding from mouth, nose, vagina or gastrointestinal tract, and low 
blood pressure. Fatal cases always end up in death within 14 days. 
  
1.1.4 PREVENTION AND TREATMENT 
Lassa fever has many kinds of unspecific symptoms, which make it hard to be diagnosed out from other diseases 
during the first stage. Malaria, shigellosis, typhoid fever, yellow fever and other viral hemorrhagic fevers may 
have similar signs as Lassa fever. Therefore, the most often detection method is using enzyme-linked 
immunosorbent serologic assays (ELISA), which detect IgM and IgG antibodies as well as Lassa antigen.  
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At an early stage, giving ribavirin, a general antiviral drug, could be effective. But there is no evidence to show 
ribavirin could be a prophylactic treatment. When the disease becomes severe, ribavirin is no longer efficient. 
General prevention is by trying all means to eliminate rodents from the human community. (World Health 
Organization, Fact sheet N°179) 
 
1.2 LASSA VIRUS 
1.2.1 CLASSIFICATION  
Lassa virus belongs to old world arenaviruse, the Arenaviridae family. The Arenaviridae family contains many 
life threatening members such as the hemorrhagic fever viruses Machupo, Junin, and the Lymphocytic 
Choriomeningitis virus (LCMV). Arenaviruses are divided into two groups, the Old World and New World, 
based on their geographical distribution and genetic differences. The Old World is found in the Eastern 
Hemisphere in places such as Europe, Asia, and Africa. While New World is found in the Western Hemisphere, 
in places such as Argentina, Bolivia, Venezuela, Brazil, and the United States. (Buchmeier MJ, et al., 2007)  
 
1.2.2 SHAPE 
Like all other Arenaviruses, Lassa virus is enveloped and has a bisegmented single-strained RNA with a unique 
ambisense genomic organization, and is coated by a nucleoprotein to form a nucleocapsid. Under cryoelectron 
microscopy, the virion looks like a grainy particle, due to its beaded nucleocapsid. That is how arenavirus gets 
its name, arena in the Latin root meaning sand.  
 
Fig 2: Transparent Electrical Microscopy micrograph of Lassa virus virions. (Picture from Ogbu O, et al., 2007) 
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Fig 3: Lassa virus structure (Image taken from Swiss Institute of Bioinformatics, 
http://viralzone.expasy.org/viralzone/all_by_species/501.html) 
1.2.3 GENOME  
Including Lassa virus, Arenaviruses’ two genomic RNA segments are large RNA (L-RNA, 7.2kb) and small 
RNA (S-RNA, 3.4kb), and they encode four known proteins: a nucleoprotein NP (60 kDa), a matrix protein Z 
(~11kDa), a RNA-dependent polymerase L (∼200 kDa), and a glycoprotein GP. Their ambisense coding 
strategy allows the polypeptides to be synthesized in two opposite directions, with the help of a noncoding 
intergenic region (IGR) folding into a hairpin structure.  
 
The small RNA encodes NP and immature GP precursor. While large RNA is responsible for L and Z. In the S 
segment, the NP coding region is transcribed from viral sense strand 3’ to 5’ into genomic complementary 
mRNA, while the GP coding region is transcribed from 5’ to 3’ into a genomic sense mRNA. The same rule 
applies to the L gene. The L protein’s mRNA is genomic complimentary and Z protein’s is genomic sense. This 
is the ambisense-coding stratagem that helps viral mRNAs being transcribed without overlapping. As a result of 
this arrangement, only after viral genomic RNA can the replication begin, opening reading frames of GPC and Z 
being transcribed. 
For precursor GP (82kDa), during the translation in the endoplasmic reticulum, a signal peptidase cleaves it into 
a signal peptide and GP-C (76kDa). After translation, subtilase SKI-1/S1P cleaves this GP-C into N-terminal 
subunit GP-1 (40 kDa) and membrane-bound subunit GP-2 (36 kDa). (Michael DB, et al., 2000)  
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Fig 4: Lassa fever virus’ virion and genome structure.  
(Image taken from Swiss Institute of Bioinformatics,	  http://viralzone.expasy.org/all_by_species/83.html) 
1.2.4 INFECTION MECHANISM 
Lassa virus infects hosts mainly by contacting, but how virions break through the epithelial barrier for 
initializing host infection is still unclear. When it reaches the host cell, the α-dystroglycan (α-DG), a 
multipurpose receptor for the extracellular matrix protein, becomes the essential receptor and helps Lassa virus’ 
endocytosis to enter the cell. The GP protein plays the role for receptor recognition. GP1 (N-terminal) locates at 
the glycoprotein spike to bind receptor α-DG on the cell surface. GP2 (C-terminal) binds to membrane and is 
responsible for transmembrane fusion. When the pH is under 5 (the ideal value), membrane fusion happens, 
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followed by the viral nucleocapsid entering a late endosomal partition via vesicular trafficking. This process is 
independent from molecular motors like clathrin, caveolin, dynamin or actin. However, some cholesterol from 
the membrane is required. The unusual endocytosis pathway allows Lassa virus particles being delivered to late 
endosomes more rapidly, thus makes infection more effective. (Schlie K, et al., 2010)  
 
Old world arenavirus LASV and LCMV share the same cell-entering mechanism. However, new world 
arenaviruses recognize different cell receptors and need molecular motors when entering a cell, and depend on 
Rab5 for delivering into early endosome, and require Rab7 as well for transmitting to late endosome (Fig 5). 
(Kunz S. 2009)  
 
 
Fig 5: Different receptor binding and cell entry mechanisms between Old World and New World arenaviruses 
(Picture taken from Kunz S. 2009) 
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1.2.5 PROTEINS 
Glycoprotein GP 
The GP protein is encoded by the S-segment RNA. Its function is to recognize and bind to the receptor of host 
cell surface and fuse into the cell. The process has been introduced above. 
 
Ring finger protein Z 
The Z protein is a matrix protein, which plays essential roles in virus assembly and budding. Expressing only Z 
without other viral proteins can be enough to form and release the enveloped Z-containing particles, which is 
not notably different from Lassa virus particles in morphology and size. Z acts as the driving force during virus 
particle releasing. Z also has strong association with the membrane. In addition, Z is assumed to interact with 
NP during viral assembling. (Shtanko O, et al., 2010)  
 
RNA-dependent polymerase L 
L protein is a putative RNA-dependent RNA polymerase. It controls the synthesis of mRNA terminating in the 
intergenic region, and noncapped genomic or antigenic RNA forming a full-length genome copy. (Lelke M, et 
al., 2010) 
The L protein consists of 2300 amino acids, which can be divided into three domains, N-terminal domain, 
central domain and C-terminal domain. It is believed to harbor several enzymatic functions in the N and C 
terminals, but this is yet unproven. Cap-snatching is supposed to be one of the L protein’s significant functions.  
With NP, L protein can form the minimal trans-acting factors in genome replication and replication. Both L and 
NP N-terminal domain are believed to cooperate with each other in a cap-snatching mechanism. The central 
domain (residues 1000-1500) of L is regarded as the RNA-dependent RNA polymerase. (Lelke M, et al., 2010)  
 
1.3 NP PROTEIN 
1.3.1 BACKGROUND 
NP is the most abundant viral protein in an LASV infected cell. NP associates with RNA to form the 
ribonucleoprotein (RNP) core protecting the genomic RNA and the nucleocapsid serves as a template for L 
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protein for RNA replication and transcription. NP also interacts with the matrix protein Z during viral assembly. 
(Eichler R, et al., 2004)  
However, the most interesting function of NP is to suppress the host cell immune responses. Moreover, LAVS 
NP structure is the only NP structure reported among Arenaviridae family. 
In human cells, there are several receptors, which play essential roles in sensing infections by detecting 
pathogen-associated pattern molecules (PAPM) and trigger immune response pathways. It is well known that 
cytoplasm receptors retinoic acid-inducible I receptor and melanoma differentiation-associated 5(MDA-5), and 
membrane toll-like receptors can detect PAMP molecules. PAMP, such as triphosphate dsRNAs, long chain 
dsRNAs or short chain dsRNAs, trigger immune response pathways to produce interferon, when virus infections 
occur. Virus infection usually produces dsRNA in the infected cell. Once retinoic acid-inducible I (RIG-I), 
melanoma differentiation-associated 5 (MDA-5) or other cellular immune receptors detect dsRNA, signaling 
will trigger IFNs production. LAVS NP has been demonstrated to play an essential role in immune suppression, 
and its 3’-5’ exonuclease activity has been shown to be crucial for the function. Our hypothesis is that the LAVS 
NP can specifically recognize and degrade the PAMP RNA molecules generated from the virus infection. 
Therefore the receptors cannot detect the infection, and no immune response occurs. (Kathryn MH, et al., 2011)  
1.3.2 STRUCTURE 
The NP coated viral genomic RNA to formed nucleocapsid, a beads-like viral particle under microscopy. The 
LAVS NP consists of two parts: amino (N) terminal and carboxy (C) terminal domains. A positively charged 
groove locates between the two domains and the viral genomic RNAs are expected to bind in the groove. All the 
structures of published nucleoprotein structures among all negative-stranded RNA viruses share the same 
organization. 
In each NP protomer, a Zn2+ locates in the C-terminal domain, forming a zinc finger structure. As a 3’-5’ 
exonuclease, one Mn2+ molecule was identified in the C-terminal domain active site. In the N-terminal domain, 
the electrostatic surface potential map indicates a RNA-binding cavity entrance. 
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Fig 6: NP monomer structure 
Yellow region represents N-domain. Blue region represents C-domain, PDB code 3MWP.  
(Picture taken from Qi X, et al., 2010) 
 
Fig 7: The ring shape form of the NP trimer  
Navy, sapphire and magenta regions show three identical molecules forming a trimer, PDB code 3MWP.  
(Picture taken from Qi X, et al., 2010) 
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1.3.3 FUNCTION 
The N-terminal domain of LAVS NP forms a deep cavity for cap binding. The 5’ terminal m7G cap is presented 
on most eukaryotic mRNAs. For most RNAs, elimination of the cap structure causes a loss of stability, 
especially against exonuclease degradation, and a decrease in the formation of the initiation complex of mRNAs 
for protein synthesis. In addition, a cap requirement has been observed for splicing eukaryotic substrate RNAs. 
Only mRNAs with a ‘cap’ structure at its 5’ end can be translated into protein by the ribosome. But arenavirus 
cannot produce cap from their own viral mRNA, therefore Lassa virus has to snatch cellular mRNAs’ caps. 
During the cap-snatching, L protein’s N terminal domain is an endonuclease that cleaves off the 5’ end of 
cellular mRNAs, while the NP’s N terminal domain holds the 5’ end cap. The holding function has not been 
reported in any equivalent protein among any other virus family.	  (Qi X, et al., 2010)  
 
Fig 8: The electrostatic surface potential map of NP. The dashed white line represents the cap-binding cavity. 
Electropositive residues are blue, electronegative residues are red. (Picture taken from Qi X, et al., 2010) 
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Fig 9: A cap analogue molecule dTTP located in the cap-binding site. The initial FoFc difference density map 
for dTTP is in blue, with pink atoms representing carbon. Yellow residues are for the deep cavity site. Green 
residues are the pass for another mRNA to enter, PDB code 3MX2. (Picture taken from Qi X, et al., 2010) 
 
The C terminal domain structure is similar to 3’-5’ exonucleases, especially the human DNA 3’-5’ exonuclease 
enzyme TREX1. Experiments also show the C terminal domain alone can digest RNA substrates and suppresses 
immune responses, which means that the C-terminal domain is the functional part for the exonucleases activity.  
 
 
Fig 10: Structure of LAVS NP C-terminal domain. Right side shows Zn2+ and its coordination,	  PDB code 3Q7B. 
(Modified from Kathryn MH, et al., 2011) 
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Fig 11: NP C-terminal domain with Mn2+, showing the essential residues for exonuclease activity. Purple 
colored residues match to DEDDh exonuclease, PDB code 3Q7C (Modified from Kathryn MH, et al., 2011) 
 
However, how NP binds and degrades PAMP molecules, such as dsRNA is not exactly clear, for no complex 
crystal has been reported. Therefore, my work focuses on expression, purification and crystallization of LAVS 
NP C-terminal domain in complex with PAMP molecules, figuring out the novel mechanism. 
I have built an expression construct of the native NP C-domain and carried out mutagenesis on designed sites. 
Protein expression and purification were successful. I’ve set up crystallization trials and get nice crystal 
complex of native NP C-domain with RNA ligand. The crystals have been sent to Diamond IO3 for X-ray 
diffraction, and the structure of the complex is solved. 
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2 MATERIALS AND METHODS 
2.1 EXPRESSION CONSTRUCT 
2.1.1 CLONING NP C-TERMINAL DOMAIN’S NUCLEOTIDES INTO PLOU3 (HIS-TAG-MBP ATTACHED) 
The nucleotides encoding the LAVS NP C-terminal domain from residue 364 to 569 was cloned into the 
pMAL-c2X-derived plasmid pLou3, with a 6His-tag at N terminus of MBP (maltose binding protein) and a 
TEV cleavage site between the MBP and the target protein. This construct was transformed into Rosetta cells 
(Novagen). The transformed cells have antibiotic resistance against ampicillin and chloramphenicol. Xiaoxuan 
Qi previously built this construct in our group. 
 
2.1.2 CLONING THE NP C-TERMINAL DOMAIN INTO PHISTEV PLASMID 
The nucleotides encoding the NP C-terminal domain were also inserted into pHisTEV plasmid. The forward and 
reverse primers containing the NCOI and HindIII enzyme cutting sites were synthesized in Eurogentec. The 
C-terminal nucleotides were amplified by PCR using a program of heating at 95°C for 2 mins, annealing at 
58°C for 1 min and extending at 72°C for 2 min for 32 cycles. The pHisTEV plasmid was cut by restriction 
enzymes NCOI and HindIII. The NP C-terminal domain PCR product was then inserted into the pHisTEV 
plasmid with the help of T4 DNA ligase (10 µl reaction system in 37°C for 2 hour. See appendix Ⅳ). 
This reconstructed plasmid was transformed into TAM1 cells for producing and harvesting more plasmids 
(transform method and plasmid extraction with miniprep method see appendixⅤ). Enzyme digestion was used 
to confirm the correct insertion (NCOI and HindIII cutting reconstructed plasmid). Afterwards, the correct 
plasmid was transferred into expression system Rosetta cells. 
 
2.1.3 MUTAGENESIS OF PHISTEV NP C-TERMINAL DOMAIN.  
DNA primers were designed based on QuikChange™ Site-Directed Mutagenesis and Huangting Liu’s protocol, 
and were synthesized at Eurogenetec. (Details given in appendix I)  
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The mutant plasmids were generated using the primers and Promega Pfu DNA Polymerase. Five units of Dpn I 
were used to remove the original template plasmids by incubation at 37°C for 2 hrs.  
Agarose gel electrophoresis was used to separate the C-terminal mutant plasmid DNA band from others. One 
micro liter of each mutant plasmid was transformed into TAM1 cells, and the transformed cells were spread on 
LB agar gel containing 100µg/ml ampicillin. Two colonies from each mutant were picked and each colony was 
inoculated into 10 ml of LB containing 100µg/ml ampicillin and cultured overnight. The mutant plasmids were 
extracted with Qiagen miniprep kit, and 5µl of each plasmid was sent to University of Dundee for sequencing. 
The correct mutant genes were transformed into Rosetta cells for expression. 
2.2  PROTEIN EXPRESSION AND PURIFICATION 
2.2.1  FOR THE NP C-TERMINAL DOMAIN (HIS-TAG-MBP ATTACHED) 
The single colony of the Rosetta transformed cells was inoculated into 500ml LB containing 50µg/ml ampicillin 
and 34 µg/ml chloramphenicol and was cultured overnight in incubator at 200 rpm in 37°C. This overnight 
culture was then subcultured to 10 liters of LB (containing 50µl/ml ampicillin and 34 µg/ml chloramphenicol) at 
200 rpm at 37°C. When OD600 reached 0.6, the cells were induced with 0.03mM final concentration of IPTG 
(isopropyl-beta-d-thiogalactopyranoside). And the protein expressions were induced at 20°C for around 20 
hours. 
 
The cells were harvested by centrifugation at 10000g for 15 mins. The Cell pellet was resuspended in loading 
buffer (20mM Tris-HCl, pH7.5, 10mM imidazole, 300mM NaCl, 10% glycerol), 1 tablet of EDTA-free protease 
inhibitor (Roch), 1µM DNase (Sigma), 1µM lysosome (Sigma) and 1mM PMSF (phenylemethylsulfonyl 
fluoride, Sigma). Cells had gone through cell disrupter twice for an adequate disruption. The debris is removed 
by centrifugation at 40000g for 30 mins. Supernatant was collected and applied to 10 ml Ni-NTA agarose 
(Qiagen) beads, which was pre-equilibrated with the loading buffer. The beads were washed with 40ml of 
loading buffer (however, even 30mM imidazole wash buffer would wash away some target protein), and were 
eluted with 22ml elution buffer consisting of 20mM Tris-HCl, pH 7.5, 500mM imidazole, 300mM NaCl 
and10% glycerol.  
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Then the protein buffer was changed to a buffer containing 20mM Tris-HCl, pH 7.5, 300mM NaCl and 10% 
glycerol, by going through a desalting column (Hiprep 26/10, GE). The His-MBP-NPC fusion protein was 
cleaved by TEV proteinase at room temperature for around 18 hours. Afterwards, the cleavage sample was 
applied to Ni-NTA agarose beads (pre-equilibrated with desalt buffer). The His-MBP was removed from the 
sample by Ni-NTA, while the target protein went through the beads column.  
 
The sample was concentrated to 7.5ml for gel filtration. The gel filtration column was pre-equilibrated with GF 
buffer (20mM Tris-HCl, pH7.5, 300mM NaCl, 10% glycerol for high salt concentration condition, or 20mM 
Tris-HCl, pH7.5, 100mM NaCl, 10% glycerol for low salt concentration). The fractions containing the NP 
C-terminal domain were pooled. The protein was concentrated to 10mg/ml and frozen in liquid nitrogen, then 
stored at -80°C. 
 
2.2.2 FOR THE HIS-TAGGED NP C-TERMINAL DOMAIN (NATIVE AND MUTATIONS) 
The His-tagged NP C-terminal domain was expressed in Rosetta E. coli cells. The overnight cultures grew in 
incubator at 37 °C and 200rpm in 500 mL LB (supplemented with 50 µg/ml kanamycin and 34 µg/ml 
chloramphenicol). The overnight culture was inoculated into 10 L LB containing 50 µg/ml kanamycin, 34 µg/ml 
chloramphenicol and 100 µM ZnCl2. When OD600 reached around 0.4, the protein was induced with 500 µM 
IPTG for around 20 hours at 25 °C and 200 rpm.  
 
The cells were harvested by centrifugation at 10000g for 15 min. The cell pellet was resuspended in loading 
buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole), 1 tablet of EDTA-free protease inhibitor 
(Roch), 1µM DNase (Sigma), 1µM lysosome and 1mM phenylemethylsulfonyl fluoride (PMSF, Sigma). Cells 
had gone through cell disrupter twice for an adequate disruption. The debris is removed by centrifugation at 
40000g for 30mins. 
 
The supernatant was pooled and applied to 10 ml Ni-NTA agarose (Qiagen) beads (pre-equilibrated with 
loading buffer). The Ni-NTA beads were washed three times with 50 mL of wash buffer (50 mM Tris-HCl, pH 
8.5, 300 mM NaCl and 30 mM imidazole), and the protein was eluted with 22ml elution buffer (50mM Tris-HCl, 
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pH 7.5, 500mM imidazole, 300mM NaCl). The protein was concentrated and purified by gel filtration using a 
Superdex 200 (GE Healthcare) column, which was equilibrated with GF buffer (20 mM Tris-HCl, pH 7.5, 300 
mM NaCl and 10% glycerol). The NP C-terminal domain samples were pooled, concentrated and stored at 
-80 °C for binding future affinity trials. 
2.3 SDS-PAGE GEL 
SDS-PAGE was used for checking protein purity in specific fractions after gel filtration. The gel was pre-cast 
NuPAGE 4-12% Bis-Tris gel, and the power supply was Powerease 500. A15µl sample was mixed with 5µl of 
SDS loading buffer and incubated at 95 °C for 5 min. Protein molecular standard (Mark12) was used to indicate 
protein molecular weight. 
 
2.4 TRIPHOSPHATE-DSRNA CONSTRUCTION 
The triphosphate dsRNA was produced with MEGAshortscript Kit according to the manufacture’s manual. The 
DNA templates for RNA were synthesized by Eurogentec.  
 
2.4.1 TEMPLATE DNA PREPARATIONS:  
The 50µl 100µM T7poly_sense_common and the 50 µl 100µM T7_anti_polyGC8 were mixed together, 
incubated at 95°C for 3min, and then cooled down to room temperature. 
 
2.4.2  TRANSCRIPTION REACTION 
The reaction takes place in a sterilized 1.5ml eppendorf tube. The 20µl reaction contains 2 µl T7 10X reaction 
buffer, 2µl T7 ATP solution (75 mM), 2µl T7 CTP solution (75 mM), 2µl T7 GTP solution (75 mM), 2µl T7 
UTP solution (75 mM), 2µl T7 enzyme Mix, 3µl template DNA and 5µL water (nuclease-free). 
 
The 20µl reaction system was mixed thoroughly, and incubated at 37°C overnight. 
In order to degrade the template DNA, 1µl of TURBO DNase was added to the system and mixed well, with 
incubation at 37°C for more than 1 hour. 
This reaction is terminated with 115µl nuclease-free water and 15µl ammonium acetate stop solution. 
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2.4.3 RNA PURIFICATION 
The RNAs were extracted with an equal volume (151µl) of phenol/chloroform (water-saturated), and then with 
an equal volume (151 µl) of chloroform. The aqueous phase was collected into a new tube. The RNAs were 
precipitated by adding 2 volumes of ethanol (approximately 600µl) and mixing well and keeping at –20°C for 
least 15 minutes. 
The RNA was pelleted by centrifugation at 4°C for 15 minutes at maximum speed (≥10,000 x g), and the 
supernatant was carefully removed. The RNA pellet was washed with 70% ethanol at -20 °C and dried at room 
temperature.  
 
2.4.4 DSRNA PREPARATION 
The synthesized RNA was dissolved in TEA buffer (10 mM Tris-HCl, pH 8, 1mM EDTA, 0.1M NaCl), around 
10µl for 5 20µl-scale reactions. The RNA sample was heated at 95 °C for 3min and annealed at room 
temperature, forming triphosphate double strand RNA. The RNA samples were quantified by Nano drop and 
store at -80°C for crystallization and assays. 
 
2.5 CRYSTALLIZATION 
Crystallization conditions were screened on a SWISSCI 'MRC' 2-Well Crystallization Plates (Douglas) with the 
sitting drop vapor diffusion method set by the Honeybee system. Each drop contained 0.15µl protein-RNA 
complex and 0.15µl buffer, while 85µl buffer was loaded in each reservoir. The crystallization screens are 
stochastic screens, made in JHN laboratory. The NP C-terminal domain RNA complex was formed by mixing 
protein and dsRNA at 1:1 molar ratio (approximately 100µl 10mg/ml protein with 4.2µl 10mM dsRNA). 
Initial crystals were obtained in 18.5% (w/v) PEG MME 5000, 0.1M Na-citrate, pH 4.5, 2.4% (w/v) PEG 
MME350 at room temperature for 2 weeks. Crystallization optimization was carried out with varying the 
concentration of PEG MME 5000 and PEG MME350 and pH. The best crystals grew in18%-19.5% (w/v) PEG 
MME 5000, 0.1M Na-citrate, pH 4.2-4.5 and 2.4% (w/v) PEG MME350.  
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2.6 X-RAY CRYSTAL DATA COLLECTION 
The crystals were frozen in liquid nitrogen using paraffin oil as a cryoprotectant. To obtain the NP C-terminal 
domain in complex with dsRNA and Mn2+, the crystals were soaked in a solution containing additional 100 mM 
MnCl2 and 20% glycerol for 1 min or 1.5 min or 5 min or 10 min before being frozen.  
The diffraction data were collected at the Diamond Light Source UK. Crystals were screened at beamline IO3 
with Pilatus 6M-F detector. Some of the good crystals were selected for data collection. Approximately 800 
frames have been recorded for each crystal. The parameters used for data collection for NP C-terminal domain 
in complex with dsRNA are listed in Table 1.  
 
Table 1: Data collection parameters for a crystal of NP C-terminal domain in complex with dsRNA 
Wavelength (constant) 0.9762 Å  
 
Energy 12.701 keV 
Omega start 144.0 ° 
Oscillation range 0.1° 
Exposure Time 0.1 s 
Detector Distance 391.4 mm 
Resolution at edge 2.0 Å 
Xbeam 1222.62 mm 
Ybeam 1264.49 mm 
 
2.7 STRUCTURE DETERMINATION, REFINEMENT AND MODEL BUILDING 
All the data were indexed and integrated using Mosflm (Geoff GB, et al., 2011), and the data were scaled using 
Scala	  (Evans P, 2006). The structure was determined by molecular replacement using Phaser (McCoy AJ. 2007). 
The initial search model was NP C-terminal domain (PDB code 3MWP). The models were built using Coot 
(Emsley P, et al., 2010), and the refinements were carried out using REFMAC5 (Garib NM, et al., 2007).  
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3 RESULT AND DISCUSSION  
3.1 PROTEIN PURIFICATION 
3.1.1 HIS-TAG-MBP FUSION PROTEIN  
The NP C-terminal domain was successfully expressed as a His-tagged MBP fusion protein. The entire fusion 
protein was purified using 10 ml of nickel beads. After washing with 30 mM imidazole, we could obtain 
relatively pure fusion protein using 22 ml of the elution buffer as shown in Fig 12. The His-tagged MBP is 
cleaved off by TEV proteinase. To find the best time for cleavage, we did a time course and found that 15 hours’ 
TEV cleavage is insufficient. We therefore always tried to cleave the MBP for 18 to 20 hours.  
 
 
Fig 12:  Purification of the MBP and N-terminal domain fusion protein and TEV proteinase cleavage. 
 
However, gel filtration cannot separate MBP and NP C-terminal domain because their molecular weight is 
similar (Fig 13) 
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Fig 13: The C-terminal domain could not be separated from MBP by gel filtration. Lane 1 is marker, lane 2 to 9 
are different fractions from the gel filtration. 
 
In order to remove MBP from the C-terminal domain, an additional nickel column was used before gel filtration. 
One effective way was to connect extra Ni-NTA columns (5ml) along with the gel filtration column, and we 
found that two Ni-NTA columns gave us the best result (Fig 14 and Fig 15). 
 
Fig. 14: NP C-terminal domain purification by a Ni-NTA column connecting to gel filtration column. 
 
 
Fig 15: NP C-terminal domain purification by two Ni-NTA columns connecting to gel filtration. 
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We have found that it did not reduce the protein yield using the two Ni-NTA columns to remove the MBP, 
compared with using one Ni-NTA column.  
 
Two different gel filtration buffers were applied in this experiment: high salt condition (20mM Tris-HCl, pH 7.5, 
300mM NaCl, 10% glycerol), and low salt condition (20mM Tris-HCl, pH 7.5, 100mM NaCl, 10% glycerol) 
 
Gel filtration result and SDS-PAGE gel picture under high salt condition: 
 
Fig.16: gel filtration graph. There are two peaks, and both of them were the NP C-terminal domain 
 
Fig. 17: NP C-terminal domain purification after gel filtration in high salt buffer. 
 
Gel filtration result and SDS-PAGE gel picture under low salt condition: 
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Fig.18: Gel filtration graph under low salt concentration. There are two major peaks, both of them were NP 
C-terminal domain. The third tiny peak shows nothing on SDS-PAGE gel, which could be just jam signal. 
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Fig 19:  SDS-PAGE gel of gel filtration purification in low salt buffer 
 
Both peaks were confirmed by SDS-PAGE and mass spectrometry as they both were the NP C-terminal domain. 
However, the second peak contains much less protein and we hardly got enough amount of protein from this 
peak after concentration. Therefore, we mainly focused on the first peak for crystallization. And the yield was 
around 1mg protein per liter culture in high salt buffer, or a bit less around 0.7mg protein per liter culture in low 
salt buffer. 
 
3.1.2 HIS-TAGGED NP C-TERMINAL PROTEIN  
The His-tagged NP C-terminal domain was expressed successfully. The protein yield is higher, around 6mg 
protein per liter cell culture, while the MBP-fusion one got 1mg protein per liter cell culture. But the purity of 
the purified protein was not as good as the His-tagged MBP fusion protein. We did not cleave the His-tag away 
as the protein would be used for surface plasmon resonance (SPR) assays. To improve the protein purity, we 
used 50 mM imidazole as washing buffer, instead of 20 mM imidazole. 
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Fig.20: SDS-PAGE shows His-tagged NP C-terminal domain purification by a nickel column 
 
The gel filtration graph showed that there is mainly one peak (Fig. 21). We obtained 5ml of the purified 
C-terminal domain with a concentration of 5mg/ml. 
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Fig. 21: gel filtration graph. 
 
The SDS-PAGE revealed that we had obtained a reasonably pure protein (Fig 22).  
 
Fig 22: SDS-PAGE gel of gel filtration of His-tagged NP C-terminal domain. Lane 2 to 9 are different fractions 
from the gel filtration 
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3.2 CRYSTALLIZATION 
The NP C-terminal domain, purified from a His-tagged MBP fusion protein was used for crystallization. 
We obtained the native crystals of NP C-terminal domain as shown in Fig 23. As our goal is to determine the 
NP C-terminal domain in complex with PAPM molecules, we focused on the crystals of NP C-terminal domain 
in complex with PAPM molecules, such as dsRNA and triphosphate dsRNAs. 
 
  
Fig 23: Crystal pictures of the native NP C-terminal protein.  
Left one was screen result using honeybee system. Right one was optimization trials result. 
 
A 6 nucleotide-length dsRNA, an 8 nucleotide-length dsRNA and a 12 nucleotide-length dsRNA were 
chemically synthesized in Eurogentec. Only the 8 nucleotide-length dsRNA formed crystals with NP C-terminal 
domain. The crystals of the NP C-terminal domain with dsRNA are shown in Fig 24. These crystals were thin. 
Although intensive optimization was carried out, we could not improve the crystals. We therefore tried to 
synthesize 8 and 12 nucleotide-length triphosphate dsRNAs with MEGA shortscript kit. We have tried to 
co-crystallize the triphosphate dsRNA with the C-terminal domain. 
 
  
Fig 24: NP C-terminal domain protein with dsRNA 8 complex crystal 
Left one was screen result using honeybee system. Right one was optimization trials result. 
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The crystals of the NP C-terminal domain in complex with triphosphate 8 nucleotide length dsRNA are shown 
in Fig 25. Those crystals can grow very fast and big in Crystal Clear P (Douglas) plates. Protein-RNA complex 
crystals appeared in less than 24 hours, and these crystals took about a week to grow large enough for X-ray 
diffraction. 
  
Fig 25:  Crystals of NP C-terminal domain protein in complex with triphosphate dsRNA 8. The crystals that 
grew from the screening are shown on the left and the crystals after optimization were shown on the right. 
 
The crystal that was used to collect data on Diamond beam line IO3 is shown in Fig 26. The rhombus shaped 
crystal is approximately 150µm long and 40µm wide.  
 
Fig 26: Crystal of NP C-terminal domain protein in complex with triphosphate dsRNA 8  
in loop for X-ray diffraction 
 
 
The diffraction pattern of the crystal is shown in Fig 27. The crystal diffracted to 1.73 Å and shows clearly 
defined diffraction spots. This diffraction pattern shows no strong ice rings and the frequency of the diffraction 
spots infers a large space group. 
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Fig 27: One of the diffraction images, collected on Diamond Light Source UK, beamline IO3. The resolution of 
the outer circle is 1.7 Å. Picture on the right side is the enlarged area of red square on the left side picture. 
3.3 CRYSTAL STRUCTURE 
The collected data were processed, and the results were listed in Table 2. After molecular replacement and a few 
cycles of refinement, the electron density for the dsRNA was very clear. However, we did not see electron 
density for the triphosphate. A dsRNA (GGGC/CCCG) was built in the electron density, which shows that the 
3’-end nucleotide (cytosine) of chain GGGC is directly located in the 3’-5’ exonuclease active site (Fig 28, 29).  
 
Table 2: The crystallographic statistics of the NP C-terminal domain in complex with triphosphate dsRNA 
Data Statistics  
Space Group 
Unit Cell parameters 
P3 
a = b 177.16 Å 
c 56.49 Å 
α=β 90° 
γ 120° 
Resolution range 46.5-1.73 Å 
Average redundancy 5.6 (5.5) 
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Unique reflections 184629 (5543) 
I/σI 16.4 (4.2) 
Completeness 99.7% (99.9%) 
Rmerge 7.3% (39.3%) 
Refinement Statistics  
Rfactor 17.80% 
Rfree 19.87% 
Rmsd bonds 
Number of protein atoms 
0.03 Å / 2.45° 
9076 
Mean B-factor 25.27 Å 
Residues in Ramachandran core 
Residues in disallowed regions 
96.83% 
0 
  
 
 
Fig 28: Electrostatic surface potential map of the NPC and dsRNA complex, and dsRNA is shown in stick. The 
cleaving strand of dsRNA main chain is located in a blue belt formed by positive charge residues.	  The blue area 
represents positively charged residues and the red area represents negatively charged residues. 
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Fig 29: LAVS NPC and dsRNA complex structure in cartoon, the manganese ion shows as magentas ball and 
Zinc ion shows as grays ball. 
 
From the structure we can see that one strand (5’GGGC3’) of the dsRNA interacts extensively with NP residues 
D466, D389, Gln462, D533, R492, E391, H528 and S430, in which most of them are catalytic residues, while 
another strand (5’GCCC3’) interacts with side chains of NP residues Y429, D426, Q425, Q422, R393 and D465. 
Particularly, the side chain of residue Y429 stacks against the guanidine ring (Fig 30, 31).    
 
 
Fig 30: Close stereo view of the interaction residues in cartoon. Dotted line shows the interaction part between 
residues and RNA. There is 3° difference between left and right pictures. 
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Fig 31: Interactions between LAVS NPC and triphosphate dsRNA and dsRNA cleavage activities of LAVS 
NP-C mutants. a, Residues are involves in the dsRNA binding and cleavage. The cleavage chain of the dsRNA 
in purple and the binding chain in cyan. b. Schematic representation of LAVS NPC and triphosphate dsRNA 
interactions. The scissile bond is indicated with a scissor. 
 
 
In order to validate the functions of the binding residues in dsRNA recognition and cleavage, we have generated 
several alanine substitute mutant constructs (name of mutant sites and primer details were shown in appendix II), 
and we are purifying the mutant proteins. We will try ITC and SPR to check the mutant binding affinities with 
different RNA ligands, such as dsRNA, triphosphate dsRNA and ssRNA. In the same time, we will check 
whether the mutant proteins process the PAPM RNA differently in efficiency.  
 
 
3.4 MUTAGENESIS AND MUTANT PROTEIN PURIFICATION 
3.4.1 PHISTEV NP C-TERMINAL DOMAIN PLASMID CONSTRUCTION 
The gene fragment encoding the NP C-terminal was inserted into pHisTEV plasmid successfully, 
confirmed by the restriction enzyme digestion result (Fig 32). The constructed plasmid was digested 
with NCOⅠ and HindIII. And the digested plasmid had been run through a 10% agarose gel. The gel 
showed that the NP C-terminal domain encoding gene band was around 600bp, corresponding to the 
exactly size for the NP C-terminal domain encoding gene 615bp. 
a. b. 
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Fig 32: The electrophoresis gel of digested NPC-pHisTEV 
3.4.2 SINGLE SITE PLASMID MUTAGENESIS 
The PCR result of a mutation is shown in Fig 33. Those plasmids were around 6kbp, equivalent to the length of 
pHisTEV vector. 
 
Fig 33: PCR result for mutations 
The DNAMan software had been used to compare the mutation sequences results with NP C-terminal domain 
encoding gene. Only the desired constructed plasmids were selected to transfer to Rosetta cells for expression. 
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3.4.3 EXPRESSION AND PURIFICATION 
The mutants were obtained by using the same expression and purification method as for the native pHisTEV NP 
C-terminal domain. The single site mutation proteins were expressed well as the native protein, around 5 to 6mg 
protein per liter culture. Fig 36 and 37 were S430A result features as an example of all mutants. 
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Fig 34: gel filtration graph on S430A mutant. There is one main peak of protein. 
 
Fig 35: SDS-PAGE gel of gel filtration of S430A mutant. Lane C9 to D9 were different fractions of main peak 
from gel filtration. 
NP mutant S430Aà 
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4 FUTURE WORK 
 
LAVS NP and other arenavirus’s NPs use a totally novel way to evade the human immune responses. To find 
the detail of the mechanism is important for the controlling of such deadly infectious diseases caused by some 
arenaviruses. Our collaborators at Emory University have shown that the LAVS NP can process dsRNA much 
quicker than those of ssRNA (approximate 20 times faster), and our structure of dsRNA and C-terminal domain 
sheds an important light on the mechanism.  
In order to elucidate the NP C-terminal’s immune suppression function, the mutant proteins have been designed, 
expressed and purified. Their binding affinities with different PAPM RNAs will need to be tested in future 
experiments. I’ll use florescence labeled RNAs to identify the cleavage efficiency of different mutants. Each 
mutant will interact with several designed RNAs under certain time and temperature. Then polyacrylamide gel 
electrophoresis will be used to separate bands and recognize the cleavage extent. On the other hand, a standard 
gel filtration chromatography method will be used to determine whether the NP C-terminal protein we obtained 
is monomer, dimer or trimer in different solvent condition.  
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5 THE NP N-TERMINAL DOMAIN 
The N-terminal domain of LAVS plays an essential role for cap binding. To investigate the detailed mechanism, 
we have cloned, expressed and crystallized the N-terminal domain.  
 
5.1 MATERIAL AND METHODS 
5.1.1 EXPRESSION CONSTRUCT 
The N-terminal domain consists of residues 1 to 338. The gene segment is derived from Lassa virus (Josiah 
strain), S genome. Similar way as dealing with the C-terminal domain, the N-terminal domain gene segment was 
cloned into pMAL-c2X-derived pLou3 plasmid, with a 6His-tag at the N terminus of MBP and TEV cleavage 
site between MBP and the target domain. This construct was transformed into Rosetta cells (Novagen). 
Xiaoxuan Qi previously built this construct in our group. 
 
5.1.2 PROTEIN EXPRESSION AND PURIFICATION 
The expression and purification process was very similar to those of the C-terminal domain. 
The transformed cells were cultured in LB media with 50mg/ml ampicillin and 34mg/ml chloramphenicol. The 
cells were induced with 0.03mM IPTG when the cell OD600 reached 0.6. And then the cells were cultured for 
about 20 hours at 20°C.  
 
The cells were harvested by centrifugation for 15min at 10000g. Cell pellet was resuspended in loading buffer 
(20mM Tris-HCl, pH7.5, 10mM imidazole, 300mM NaCl and 10% glycerol) with1 tablet of EDTA-free 
protease inhibitor (Roch), 1µM DNase (Sigma), 1µM Lysozome and 1mM PMSF (Sigma). The cells were 
disrupted using a cell disruptor. The cell debrides were removed by centrifugation for 30min at 40000g. The 
supernatant was collected and applied to 10 ml of Ni-NTA agarose (Qiagen) beads, which pre-equilibrated with 
loading buffer. The beads were washed with 20ml loading buffer (wash buffer with 30mM imidazole will wash 
away target protein), and the fusion protein was eluted with 22ml elution buffer consisting of 20mM Tris-HCl, 
pH 7.5, 500mM imidazole, 300mM NaCl and 10% glycerol).  
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The sample buffer was changed to desalt buffer (20mM Tris-HCl, pH 7.5, 300mM NaCl and 10% glycerol), 
using a desalting column (Hiprep 26/10, GE). The His-MBP-NPC fusion protein was cleaved by TEV 
proteinase at room temperature for 16 hours. The His-MBP was removed by Ni-NTA agarose beads 
(pre-equilibrated with desalt buffer).  
 
The sample was concentrated to 7.5ml for the gel filtration. The gel filtration column was pre-equilibrated with 
GF buffer (20mM Tris-HCl, pH7.5, 300mM NaCl and 10% glycerol as high salt concentration condition, or 
20mM Tris-HCl, pH7.5, 100mM NaCl and 10% glycerol for low salt concentration). The fractions containing 
the NP N-terminal domain were checked by SDS-PAGE gel (Invitrogen, Mark12) and pooled. The purified 
N-terminal domain was concentrated to 20mg/ml, frozen by liquid nitrogen and stored at -80°C. 
 
5.1.3 CRYSTALLIZATION 
Crystallization conditions were screened on MRC plates with the sitting drop vapor-diffusion method using a 
Honeybee robot. Drops contained 0.15µl protein solution and 0.15µl buffer with 100µl buffer in each reservoir. 
The crystallization screens were stochastic screens, made by JHN lab.  
Initial crystals were obtained around 2~3 weeks at 20 °C in 0.5M magnesium formate dihydrate, 0.1M HEPES, 
pH 7.5. Optimizations were carried out, and the crystallization conditions were optimized to 0.2M~0.8M 
magnesium formate dihydrate, 0.1M HEPES, pH 7.1-7.9.  
 
5.2 RESULT 
The gel filtration shows that the N-terminal domain displays two peaks. Mass spectra data is needed to 
determine whether both peaks are the same N-terminal domain. The two peaks gain almost same amount of 
protein. However, only the peak two proteins formed crystals. 
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Fig 36: NP N-terminal domain gel filtration graph 
 
Fig 37: SDS-PAGE gel gel of gel filtration fractions of N-terminal domain. Lane 6 to 8 were the first peak, lane 
9 to 11 were the second peak. 
 
Crystals 
Fig 38 shows the obtained crystals of the N-terminal domain. On the left figure is the initial crystal from the 
screen and the right figure shows the crystals grown under optimized conditions. We are trying to improve the 
crystal quality. 
   
Fig 38: crystal of the NP N-terminal domain 
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5.3 FUTURE WORK 
The N-terminal domain is very important for the cap-snatching mechanism, and this mechanism is different 
from that of bunyavirus or influenza virus. To find out the detailed mechanism, I will try to improve the crystal 
quality, test whether the crystal diffracts. If I gain good diffraction data, I will then try to evaluate the cap 
binding function by obtaining the m7GpppG and N-terminal domain complex structure. At the same time, I will 
set up the in vitro assays using the NP and the N-terminal domain of the L to test how the virus from the host 
mRNAs obtains the caps.  
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6 APPENDIx I 
 
Short chain RNA sequence details 
 
For crystallization trials 
ds RNA 6：GAC-GCU 
ds RNA 8: CGC-AUG-CG 
ds RNA 12: GAC-GCU-AGC-GUC 
ppp ds RNA GC8: GGG-CGC-CC 
 
For protein-RNA binding affinity test 
ds RNA 16 forward: UCU-CUC-UCU-CUC-UCC-C 
ds RNA 16 reverse: GGG-AGA-GAG-AGA-GAG-A 
ppp ds RNA GC14: GGC-GCG-CGC-GCG-CCT-ATA-GTG-AGT-CG 
 
 
DNA template sequence details 
(For RNA synthesis) 
 
common: AAT-TTA-ATA-CGA-CTC-ACT-ATA-GG,  
GC8: GGG-CGC-CCT-ATA-GTG-AGT-CGT-ATT-AAA-TT 
GC14: GGC-GCG-CGC-GCG-CCT-ATA-GTG-AGT-CGT-ATT-AAA-TT 
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7 APPENDIX II 
DNA primer sequence details for mutants 
1_D465A_forward: CCT-GTC-AGG-GGT-CCG-CTG-ACA-TAA-GGA-AAC-TC 
  D465A_reverse: GAG-TTT-CCT-TAT-GTC-AGC-GGA-CCC-CTG-ACA-GG 
2_K469A_forward: CCG-ATG-ACA-TAA-GGG-CAC-TCC-TTG-AAT-CAC-AAG 
  K469A_reverse: CTT-GTG-ATT-CAA-GGA-GTG-CCC-TTA-TGT-CAT-CGG 
3_Q462A_forward: GGT-CAT-TAC-CTG-TGC-GGG-GTC-CGA-TGA-C 
  Q462A_reverse: GTC-ATC-GGA-CCC-CGC-ACA-GGT-AAT-GAC-C 
4_R492A_forward: CAG-CAA-AAC-TGA-TTC-CGC-GAA-GTA-TGA-AAA-TGC-AG 
  R492A_reverse: CTG-CAT-TTT-CAT-ACT-TCG-CGG-AAT-CAG-TTT-TGC-TG 
5_R468A_forward: GGG-TCC-GAT-GAC-ATA-GCG-AAA-CTC-CTT-GAA-TCA-C 
  R468A_reverse: GTG-ATT-CAA-GGA-GTT-TCG-CTA-TGT-CAT-CGG-ACC-C 
6_S430A_forward: CAG-GAT-GCT-AAG-TAC-GCA-CAT-GGG-ATT-GAT-GTC 
  S430A_reverse: GAC-ATC-AAT-CCC-ATG-TGC-GTA-CTT-AGC-ATC-CTG 
7_Y429A_forward: CAA-GCA-GGA-TGC-TAA-GGC-CTC-ACA-TGG-GAT-TGA-TG 
  Y429A_reverse: CAT-CAA-TCC-CAT-GTG-AGG-CCT-TAG-CAT-CCT-GCT-TG 
8_Y429F_forward: CAA-GCA-GGA-TGC-TAA-GTT-CTC-ACA-TGG-GAT-TGA-TG 
  Y429F_reverse: CAT-CAA-TCC-CAT-GTG-AGA-ACT-TAG-CAT-CCT-GCT-TG 
9_R492A_forward: GCA-AAA-CTG-ATT-CCG-CGA-AGT-ATG-AAA-ATG 
  R492A_reverse: CAT-TTT-CAT-ACT-TCG-CGG-AAT-CAG-TTT-TG 
10_K516A_forward: TGT-CGT-TGT-TGA-AGC-GAA-GAA-AAG-AGG 
  K516A_reverse: GCC-TCT-TTT-CTT-CGC-TTC-AAC-AAC-GAC 
11_K517A_forward: GTT-GTT-GAA-AAG-GCG-AAA-AGA-GGC-GG 
  K517A_reverse: CCG-CCT-CTT-TTC-GCC-TTT-TCA-ACA-AC 
12_truncation_515_522forward: 
CAT-GCA-CAC-AGG-TGT-CGT-TGT-T||GA-GGA-AAT-AAC-CCC-TCA-CTG 
  truncation_515_522reverse: 
CAG-TGA-GGG-GTT-ATT-TCC-TC||A-ACA-ACG-ACA-CCT-GTG-TGC-ATG 
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8 APPENDIX III 
PCR protocol based on that provided by Dr Huangting Liu. 
 
Pfu buffer              5µl 
dNTP                 5µl 
primer Forward         1µl 
primer Reverse         1µl 
template DNA       ~10ng 
pfu enzyme            1µl 
H2O to final volume of  50µl 
 
95°C    5min 
95°C    1min 
12 cycles     61°C    1min (Tm -5°C)  
72°C   12min 
95°C    1min 
61°C    1min 
72°C   30min 
 4°C   forever 
 
 
PCR protocol based on QuikChange™ Site-Directed Mutagenesis method 
Pfu buffer               5µl 
dNTP                   5µl 
primer Forward           1µl 
primer Reverse           1µl 
template DNA         ~20ng 
pfu enzyme              1µl 
H2O to final volume of    50µl 
 
95°C   1min 
95°C   30s 
13 cycles     55°C   1min 
68°C   12min 
4°C    forever 
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9 APPENDIX IV 
Restriction enzyme reaction 
buffer E   1µl 
BSA      1µl 
HindIII   0.3µl 
NCOI    0.3µl 
Plasmid    5µl 
H2O     3.3µl 
 
Reaction in 37°C for 2 hours 
Run 1% agarose gel for result checking 
 
T4 DNA ligase protocol 
vector DNA                     100ng 
insert DNA                      17ng 
Ligase 10Xbuffer                 1µl         10 µl 
T4 DNA ligase (Weiss units)      0.1~1u 
Nuclease-Free water to final volume of 10µl 
Incubate in room temperature for 3 hours, or 4°C overnight. 
10	  µl	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10  APPENDIX V 
TRANSFORM PLASMID TO COMPETENT CELLS 
1. At 4ºC, add 1µl of plasmid to a microtube with 50µL of TAM1/Rosetta competent cells and mix well; keep 
in ice for 30min 
2. Heat shock at 42ºC for 90sec, and put in ice for 2min 
3. Add 1ml of LB medium to transformed cells. Incubate at 200rpm, 37ºC for 1hour 
4. Spin down at 13000 rpm for 2min in a microcentrifuge 
5. Reject 850ml supernatant and resuspend cells pellet 
6. Spread cells on LB/KANA agarose plate (TAM 1 cell) or LB/KANA/CHLO agarose plate (Rosetta). 
Inserted plasmid contains kanamycin resistance, and Rosetta cell itself has chloramphenicol resistance. 
7. Grow cells overnight by putting the plate up side down at a 37ºC still incubator 
Plasmid extraction by QIAGEN miniprep kit 
1. Culture target cells overnight in 10ml LB media (supplemented with 34 µg/ml kanamycin for TAM1 cell, 
or 34 µg/ml kanamycin and 34 µg/ml chloramphenicol for Rosetta cell). Cell colony is picked from agarose 
plate. 
2. Transit overnight culture to 15ml centrifuge tube. Spin down 4500rpm for 10min. Discard supernatant  
3. Resuspend pelleted bacterial cells in 250 µl Buffer P1 and transfer to a microcentrifuge tube. 
4. Add 250 µl Buffer P2 and gently invert the tube 4–6 times to mix. 
5. Add 350 µl Buffer N3 and invert the tube immediately but gently 4–6 times. 
6. Centrifuge for 10 min at 13,000 rpm in microcentrifuge. 
7. Apply the supernatants from last step to the QIAprep spin column by decanting or pipetting. 
8. Centrifuge for 1min. Discard the flow-through. 
9. Wash the spin column by adding 0.5 ml Buffer PB and centrifuging for 1min. discard the flow-through. 
10. Wash spin column by adding 0.75 ml Buffer PE and centrifuging for 30–60 s. 
11. Discard the flow-through, and centrifuge for an additional 1 min to remove residual wash buffer. 
12. Place the column in a clean 1.5 ml microcentrifuge tube. To elute DNA, add 45 µl water to the center of 
each spin column, let stand for 1 min, and centrifuge for 1 min. 
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